Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinan Sheng

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Cancer Cell|December 10, 2024
Molecular subtyping in urothelial carcinoma treatmentXiaowen Wu, Xinan Sheng
JAMA Oncology|April 9, 2026
Challenges in Interpreting MELATORCH Trial Outcomes-ReplyJuan Li, Xinan Sheng, Jun Guo
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 9, 2026
Breakthroughs in malignancy therapy: New advances and emerging trends in renal cell carcinomaXieqiao Yan, Xiaowen Wu, Xinan Sheng
International Urology and Nephrology|March 25, 2026
Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysisCiting Guo, Jinchang Wei, Yajie Wang, et al.
BMC Cancer|February 26, 2011
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive casesZhihong Chi, Siming Li, Xinan Sheng, et al.
BMC Cancer|June 3, 2014
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinomaSiming Li, Yan Kong, Lu Si, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Development of <sup>99m</sup>Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murineXiaoyi Guo, Hua Zhu, Teli Liu, et al.
Future Oncology (London, England)|July 31, 2018
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III dataXinan Sheng, Feng Bi, Xiubao Ren, et al.
Cancer Biology & Medicine|September 23, 2025
Advances in antibody-drug conjugates for urothelial carcinoma treatmentJinchang Wei, Bixia Tang, Xieqiao Yan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2011
A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patientsLili Mao, Lu Si, Zhihong Chi, et al.
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Cancer Cell|December 10, 2024
Molecular subtyping in urothelial carcinoma treatmentXiaowen Wu, Xinan Sheng
JAMA Oncology|April 9, 2026
Challenges in Interpreting MELATORCH Trial Outcomes-ReplyJuan Li, Xinan Sheng, Jun Guo
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 9, 2026
Breakthroughs in malignancy therapy: New advances and emerging trends in renal cell carcinomaXieqiao Yan, Xiaowen Wu, Xinan Sheng
International Urology and Nephrology|March 25, 2026
Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysisCiting Guo, Jinchang Wei, Yajie Wang, et al.
BMC Cancer|February 26, 2011
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive casesZhihong Chi, Siming Li, Xinan Sheng, et al.
BMC Cancer|June 3, 2014
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinomaSiming Li, Yan Kong, Lu Si, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Development of <sup>99m</sup>Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murineXiaoyi Guo, Hua Zhu, Teli Liu, et al.
Future Oncology (London, England)|July 31, 2018
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III dataXinan Sheng, Feng Bi, Xiubao Ren, et al.
Cancer Biology & Medicine|September 23, 2025
Advances in antibody-drug conjugates for urothelial carcinoma treatmentJinchang Wei, Bixia Tang, Xieqiao Yan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2011
A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patientsLili Mao, Lu Si, Zhihong Chi, et al.
Pageof 14